€ 0
Key Takeaways
Risk factor
Significant default risk
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Data is available to registered users only